Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.61 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28160678 | 0.85 | HDAC6 (0.57) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL1365321 | 0.83 | HDAC6 (0.71) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL1365323 | 0.83 | HDAC6 (0.71) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL1365734 | 0.80 | HDAC6 (0.70) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL8241949 | 0.78 | HDAC1 (0.67) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL1486886 | 0.76 | HDAC1 (0.69) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL724056 | 0.76 | HDAC1 (0.69) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL17425270 | 0.76 | HDAC6 (0.76) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL28688 | 0.75 | HDAC1 (0.52) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL2732661 | 0.75 | GPBAR1 (0.52) | HDAC6HDAC1HDAC8HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | HDAC6 9/4885HDAC1 1/4885HDAC8 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.